Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caris Life Sciences (CAI) Total Current Liabilities (2024 - 2025)

Caris Life Sciences has reported Total Current Liabilities over the past 2 years, most recently at $127.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $127.1 million for Q4 2025, down 23.14% from a year ago — trailing twelve months through Dec 2025 was $127.1 million (down 23.14% YoY), and the annual figure for FY2025 was $127.1 million, down 23.14%.
  • Total Current Liabilities for Q4 2025 was $127.1 million at Caris Life Sciences, up from $86.0 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for CAI hit a ceiling of $165.4 million in Q4 2024 and a floor of $86.0 million in Q3 2025.